U.S. President Donald Trump plans to nominate Stephen Hahn, chief medical executive of the University of Texas MD Anderson Cancer Center, to lead the Food and Drug Administration (FDA).
Hahn is a radiation oncologist specializing in treating lung cancer and sarcoma. From 1996-2014, Hahn was at the University of Pennsylvania, where he was Henry K. Pancoast professor and chair of the department of radiation oncology. Hahn was a senior investigator at the National Cancer Institute (NCI) from 1989-1996.
Hahn received his medical degree from Temple University in 1984 and his Bachelor of Arts degree in biology from Rice University in 1980.
If confirmed, Hahn would succeed former FDA Commissioner Scott Gottlieb, who stepped down from the post earlier this year. Acting FDA Commissioner Ned Sharpless will return to his role at NCI, the U.S. Department of Health and Human Services announced on Friday.